FIELD: medicine. SUBSTANCE: method involves incubating ascitic fluid of a patient with various combinations of cytostatic agents in the Richlocaine presence in the concentration of 0.005 mg per 1 ml of incubated mixture. Sharp increase of dead cell number being observed in the ascitic fluid, this cytostatic agents combination is selected for performing further intraperitoneal therapy with preliminary intraperitoneally administered Richlocaine at a total dose of 10-30 ml of its 0.5% solution. EFFECT: increased antitumor activity of administered cytostatic preparations; excluded application of ineffective remedies. 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING INDIVIDUAL SENSITIVITY TO CHEMOTHERAPY IN PATIENTS SUFFERING FROM ASCITIC FORM OF III-IV STAGE OVARIAN CARCINOMA | 1999 |
|
RU2161801C2 |
METHOD OF TREATMENT OF PATIENTS WITH OVARIAN CANCER | 2007 |
|
RU2352341C1 |
METHOD FOR TREATMENT OF RELAPSES IN ONCOGYNECOLOGICAL PATIENTS | 2005 |
|
RU2296564C2 |
METHOD OF TREATMENT BREAST CANCER | 2008 |
|
RU2393888C1 |
METHOD FOR DRAINING ABDOMINAL CAVITY | 1999 |
|
RU2188044C2 |
METHOD FOR TREATING MAMMALIAN GLAND CARCINOMA | 1998 |
|
RU2158588C2 |
METHOD FOR TREATING THE CASES OF MAMMALIAN GLAND CARCINOMA | 2001 |
|
RU2203687C2 |
METHOD TO TREAT MAMMARY GLAND CANCER | 2000 |
|
RU2178294C2 |
BREAST CANCER CHEMOTHERAPY PROCEDURE | 2008 |
|
RU2372917C1 |
METHOD OF TREATMENT OF PATIENTS WITH BREAST CANCER | 1998 |
|
RU2145239C1 |
Authors
Dates
2001-02-20—Published
1999-07-14—Filed